ribavirin has been researched along with Pulmonary Embolism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, GS; Kicska, GA; Kinahan, PE; Li, T; Liu, L; Pipavath, SNJ; Wu, W | 1 |
| Bereszyńska, I; Elikowski, W; Kurosz, J; Marszałek, A; Małek, M; Mozer-Lisewska, I; Zawilska, K | 1 |
2 other study(ies) available for ribavirin and Pulmonary Embolism
| Article | Year |
|---|---|
The novel coronavirus disease (COVID-19) complicated by pulmonary embolism and acute respiratory distress syndrome.
Topics: Acute Disease; Aged; Biomarkers; Blood Platelets; Ceftazidime; COVID-19; COVID-19 Drug Treatment; Dyspnea; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Hypoxia; Lung; Male; Methylprednisolone; Middle Aged; Pulmonary Embolism; Respiratory Distress Syndrome; Ribavirin; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
[Pulmonary embolism in a 30 year-old man with chronic hepatitis C during therapy with pegylated interferon-α and ribavirin].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Pulmonary Embolism; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |